Immunocore
Immunocore:
Developer of the world’s first approved TCR-therapeutic KIMMTRAK and pioneering a new class of therapeutics to deliver transformative medicines to patients in cancer, infection, and autoimmune. KIMMTRAK generated net revenues of $34M in 2Q22 for patients with metastatic uveal melanoma. Durable clinical activity was presented (ESMO 2022) for PRAME in multiple solid tumors and have initiated four expansion arms.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Marketed, Phase III, Phase l or ll
Disease Space
Anti-infectives, Antivirals, Immuno-Oncology, Immunotherapy, Infectious Disease, Oncology, Rare Disease
Finance
Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Antibodies, Cell Therapy, Platform Technology
Website:
Profiles:
Address:
Abingdon, Oxfordshire
United Kingdom
United Kingdom
More info:
My account:
Company Participants at Solebury 1x1 Management Access Event 2023
- Bahija Jallal, CEO
- Brian Di Donato, Chief Financial Officer and Head of Strategy
- Clayton Robertson, Head of Investor Relations
- David Berman, Head of R&D
Lead Programs
Kimmtrak
| Indication | Phase |
|---|---|
| metastatic uveal Melanoma | Marketed |
| Advanced Melanoma | 2/3 |
Top 10 Holders of Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| RTW Investments LP | 12.54 | 6,029,633 | 312.94 | 13F | 6/30/23 |
| Wellington Management Co. LLP | 7.68 | 3,695,490 | 191.80 | 13F | 6/30/23 |
| Rock Springs Capital Management LP | 6.30 | 3,028,410 | 157.17 | 13F | 6/30/23 |
| Baker Bros. Advisors LP | 5.24 | 2,520,731 | 130.83 | 13F | 6/30/23 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 5.04 | 2,423,420 | 125.78 | 13F | 6/30/23 |
| T. Rowe Price Associates, Inc. (Investment Management) | 4.62 | 2,221,664 | 115.30 | Funds | 6/30/23 |
| Fidelity Management & Research Co. LLC | 3.76 | 1,810,019 | 93.94 | 13F | 6/30/23 |
| Paradigm BioCapital Advisors LP | 2.64 | 1,270,124 | 65.92 | 13F | 6/30/23 |
| General Atlantic LLC | 1.98 | 950,000 | 49.31 | 13F | 6/30/23 |
| Pictet Asset Management SA | 1.96 | 941,773 | 48.88 | 13F | 6/30/23 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.